Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice
- 30 August 2019
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (1) , 192-217
Abstract
To summarise data with radium-223 dichloride (223RaCl2), a mechanism-mediated targeted alpha therapy (TAT), in metastatic castration-resistant prostate cancer (mCRPC) and to chart the development of TAT in mCRPC and in other tumour types.Keywords
This publication has 47 references indexed in Scilit:
- Pharmacokinetics and Imaging of 212 Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer PatientsCancer Biotherapy and Radiopharmaceuticals, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancerEuropean Journal of Cancer, 2012
- Analysis of Patient Survival in a Phase I Trial of Systemic Targeted α-Therapy for Metastatic MelanomaImmunotherapy, 2011
- Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid LeukemiaClinical Cancer Research, 2010
- Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I StudyJournal of Nuclear Medicine, 2009
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studyThe Lancet Oncology, 2007
- Intralesional targeted alpha therapy for metastatic melanomaCancer Biology & Therapy, 2005
- First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal MetastasesClinical Cancer Research, 2005